7-(2-羟乙基)-1,2,3,4-四氢-1,8-萘啶 | 243641-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-(2-羟乙基)-1,2,3,4-四氢-1,8-萘啶
• 英文名称: 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol
• 英文别名: 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-ethanol；2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethan-1-ol；7-(2-hydroxyethyl)-1,2,3,4-tetrahydro-1,8-naphthyridine；5,6,7,8-tetrahydro-1,8-naphthyridine-2-ethanol
• CAS: 243641-39-6
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: WEMUNMQFXOILNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(2-羟乙基)-1,2,3,4-四氢-1,8-萘啶 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium hydride 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis

  摘要：

  The heterodimeric transmembrane αv integrin receptors have recently emerged as potential targets for the treatment of idiopathic pulmonary fibrosis. Herein, we describe how subtle modifications of the central aromatic ring of a series of phenylbutyrate-based antagonists of the vitronectin receptors αvβ3 and αvβ5 significantly change the biological activities against αvβ6 and αvβ8. This resulted in the discovery of a pan αv antagonist (compound 39, 4-40 nM for the integrin receptors named above) possessing excellent oral pharmacokinetic properties in rats (with a clearance of 7.6 mL/(min kg) and a bioavailability of 97%).

  DOI：

  10.1021/acs.jmedchem.9b00962
• 作为产物：
  描述：

  (E)-1-ETHOXY-2-(1,8-NAPHTHYRIDIN-2-YL) ethanol 在 lithium aluminium tetrahydride 、 10 wt% Pd(OH)2 on carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 20.5h， 生成 7-(2-羟乙基)-1,2,3,4-四氢-1,8-萘啶
  参考文献：
  名称：

  [EN] INTEGRIN ANTAGONISTS
  [FR] ANTAGONISTES DE L'INTÉGRINE

  摘要：

  公开号：

  WO2018132268A8

文献信息

• Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
  申请人：——

  公开号：US20040092538A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。
• Facile preparation of thiophene C2-ethers using the Mitsunobu reaction
  作者：Craig S. Harris、Hervé Germain、Georges Pasquet

  DOI：10.1016/j.tetlet.2008.07.153

  日期：2008.10

  The preparation of thiophene ethers generally requires forcing conditions thus limiting the choice of alkyl substituent. Herein, we report the first successful generally applicable conditions for the selective O-alkylation of 2(5H)-thiophenone.

  噻吩醚的制备通常需要强制条件，因此限制了烷基取代基的选择。在这里，我们报道了2（5 H）-噻吩的选择性O-烷基化的第一个成功的普遍适用条件。
• Cycloalkyl alkanoic acids as integrin receptor antagonists
  申请人：——

  公开号：US20020077321A1

  公开（公告）日：2002-06-20

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; V &bgr; 3 and/or &agr; V &bgr; 5 integrin.

  本发明涉及一类化合物，其由化学式I1表示，或其药学上可接受的盐，包括化合物I的药物组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法。
• [EN] PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] COMPOSES DE PYRAZOLE EN TANT QU'ANTAGONSITES DES RECEPTEURS DE L'INTEGRINE
  申请人：PHARMACIA CORP

  公开号：WO2004058761A1

  公开（公告）日：2004-07-15

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the α Vβ5 integrin without significantly inhibiting the α Vβ6 integrin.

  本发明涉及包含式(I)化合物的制药组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法，而不显著抑制αVβ6整合素。
• 2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System
  申请人：Kroth Heiko

  公开号：US20110092537A1

  公开（公告）日：2011-04-21

  The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

  本发明涉及2,6-二氨基吡啶化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常以及与淀粉样蛋白类似蛋白相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织中的病理异常/变化相关的眼部疾病。